GLP-Triple, also designated by its development code LY3437943, ranks among the most extensively studied molecules of the new generation of metabolic peptides. This article synthesizes, strictly within a laboratory research context ("research use only"), the current state of knowledge drawn from the scientific literature and published trials. Nothing below constitutes a medical claim or guidance for human administration.
What Is GLP-Triple?
GLP-Triple is a modified synthetic peptide belonging to the class of multi-receptor incretin hormone agonists. Its distinguishing feature is simultaneous action on three targets: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR) — hence its informal designation as a "triple agonist."
From a physicochemical standpoint, research-compound supplier data sheets report a molecular formula of C221H342N46O68, a molecular weight of approximately 4731 g/mol, and CAS number 2381089-83-2. Like other incretin-mimetic peptides, it carries a fatty acid side chain that extends its plasma half-life by promoting albumin binding. It is typically supplied as a white lyophilized powder intended for laboratory applications.
Mechanism of Action Under Study
In the pharmacological literature, interest in GLP-Triple stems from the convergence of three signaling pathways that have been studied separately for decades. GLP-1 agonism is associated, in experimental models, with glucose-dependent stimulation of insulin secretion and a slowing of gastric emptying. GIP agonism also modulates the insulin response and, according to published work, may attenuate certain gastrointestinal side effects while acting on adipose tissue.
The most distinctive component is agonism at the glucagon receptor. In preclinical models, GCGR activation is associated with increased energy expenditure and mobilization of hepatic lipids. It is this third pathway that differentiates GLP-Triple from the dual GIP/GLP-1 agonists already described in the literature.
Research Domains
Documented research directions for GLP-Triple primarily cover energy metabolism and body-weight regulation in obesity models, glycemic homeostasis in type 2 diabetes models, and metabolic-associated steatotic liver disease (MASLD/MASH). Exploratory work has also examined associated cardiometabolic parameters (blood pressure, lipids, inflammatory markers). These domains remain subjects of ongoing scientific investigation and do not imply any validated use outside the experimental setting.
What the Literature Shows
A randomized, double-blind, placebo-controlled phase 2 trial published in the New England Journal of Medicine enrolled 338 subjects over 48 weeks with weekly subcutaneous administration. At the doses studied (1, 4, 8, and 12 mg), the authors report a dose-dependent mean weight reduction reaching approximately 17.5% at 24 weeks and up to 24.2% at 48 weeks for the highest doses.
A phase 2a sub-study published in Nature Medicine evaluated hepatic steatosis in 98 participants with an MRI-measured liver fat content ≥10%. At 24 weeks, reported mean relative reductions in liver fat ranged from −42.9% (1 mg) to −82.4% (12 mg), with a notable proportion of subjects achieving normalization (<5%) by 48 weeks at the higher doses. Work published in The Lancet has further documented effects on glycemia and body composition in the context of type 2 diabetes.
More recently, the phase 3 TRIUMPH-1 program (approximately 2,339 participants, doses of 4, 9, and 12 mg over 80 weeks, with extension) reported mean weight reductions on the order of 19.0% to 28.3% at 80 weeks. These figures illustrate a consistent dose-response relationship across study phases.
Effects and Limitations Observed in Research
Across published trials, the most frequently reported adverse events are gastrointestinal in nature (nausea, diarrhea, constipation, vomiting), generally mild to moderate in intensity and occurring mainly during the dose-escalation phase. In phase 3 data, these events were more frequent at higher doses; a discontinuation rate related to adverse events of approximately 11% was reported.
The usual methodological limitations apply: selected populations, observation periods still limited for certain endpoints, and long-term safety data still being consolidated. The glucagon component, in particular, is the subject of ongoing scientific attention regarding its effects on heart rate and energy metabolism. No definitive conclusions can be drawn outside the scope of these trials.
Reconstitution & Storage
For laboratory-handling information purposes only (research use only): lyophilized GLP-Triple is most commonly reconstituted with bacteriostatic water, poured slowly against the vial wall without vigorous agitation, until fully dissolved. The working concentration depends on the volume added relative to the peptide quantity in the vial.
Research-compound technical data sheets recommend storing the powder at −20°C (stability on the order of one year), or −80°C for long-term storage, protected from moisture and light. Once in solution, stability is markedly reduced: short-term refrigerated storage, protected from light, avoiding freeze-thaw cycles. These indications pertain exclusively to the storage of a laboratory reagent.
Doses Used in Studies
The following values are presented solely as doses studied in the literature and clinical trials, for scientific understanding purposes, and do not constitute a protocol or administration guidance of any kind. Phase 2 trials explored weekly subcutaneous doses of 1, 4, 8, and 12 mg, with gradual escalation; phase 3 trials used doses of 4, 9, and 12 mg. These data originate from studies conducted in humans within a strictly regulated medical framework.
Disclaimer: product intended for laboratory research use only ("research use only"); not intended for human, diagnostic, or therapeutic use.
Summary
GLP-Triple (LY3437943) is a triple GIP/GLP-1/glucagon agonist for which the scientific literature documents marked, dose-dependent effects on body weight, glycemia, and liver fat in phase 2 and phase 3 trials. Its adverse-effect profile, dominated by transient gastrointestinal events, and its long-term safety data remain subjects of active research. All information presented here falls strictly within a documentary and laboratory research context.